A clinical study to assess whether the development of CRS is associated with outcomes in patients with aggressive large B-NHL undergoing treatment with CAR T cells
Latest Information Update: 24 Jan 2023
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Tisagenlecleucel (Primary)
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
Most Recent Events
- 24 Jan 2023 New trial record
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition